Results 61 to 70 of about 774,999 (361)

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. [PDF]

open access: yes, 2019
ObjectiveTo evaluate the efficacy of denosumab in suppressing joint destruction when added to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy in patients with rheumatoid arthritis (RA).MethodsThis was a multi-centre ...
Genant, Harry K   +9 more
core   +2 more sources

Characterizing Parental Concerns About Lasting Impacts of Treatment in Children With B‐Acute Lymphoblastic Leukemia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background B‐acute lymphoblastic leukemia (B‐ALL) is the most common pediatric cancer, and while most children in high‐resource settings are cured, therapy carries risks for long‐term toxicities. Understanding parents’ concerns about these late effects is essential to guide anticipatory support and inform evolving therapeutic approaches ...
Kellee N. Parker   +7 more
wiley   +1 more source

Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapy

open access: yesOncoImmunology, 2018
Acute infection is known to induce strong anti-tumor immune responses, but clinical translation has been hindered by the lack of an effective strategy to safely and consistently provoke a therapeutic response.
Mark Bazett   +13 more
doaj   +1 more source

A nationwide survey on patient's versus physician's evaluation of biological therapy in rheumatoid arthritis in relation to disease activity and route of administration : the Be-Raise study [PDF]

open access: yes, 2016
Objectives : Biological treatment of rheumatoid arthritis (RA) is one of the cornerstones of current treatment strategies for the disease. Surprisingly little information exists on whether the route of administration affects patients' treatment ...
Bert Vander Cruyssen   +7 more
core   +4 more sources

Revealing the structure of land plant photosystem II: the journey from negative‐stain EM to cryo‐EM

open access: yesFEBS Letters, EarlyView.
Advances in cryo‐EM have revealed the detailed structure of Photosystem II, a key protein complex driving photosynthesis. This review traces the journey from early low‐resolution images to high‐resolution models, highlighting how these discoveries deepen our understanding of light harvesting and energy conversion in plants.
Roman Kouřil
wiley   +1 more source

Predicting Antibody Developability Profiles Through Early Stage Discovery Screening

open access: yesmAbs, 2020
Monoclonal antibodies play an increasingly important role for the development of new drugs across multiple therapy areas. The term ‘developability’ encompasses the feasibility of molecules to successfully progress from discovery to development via ...
Marc Bailly   +21 more
doaj   +1 more source

Pharmacokinetic/LDL‐C and exposure–response analysis of tafolecimab in Chinese hypercholesterolemia patients: Results from phase I, II, and III studies

open access: yesClinical and Translational Science, 2023
Tafolecimab, a novel fully human monoclonal antibody targeting PCSK9, has been assessed in Chinese healthy volunteers and patients with hypercholesterolemia.
Shuling Yan   +9 more
doaj   +1 more source

Mapping the evolution of mitochondrial complex I through structural variation

open access: yesFEBS Letters, EarlyView.
Respiratory complex I (CI) is crucial for bioenergetic metabolism in many prokaryotes and eukaryotes. It is composed of a conserved set of core subunits and additional accessory subunits that vary depending on the organism. Here, we categorize CI subunits from available structures to map the evolution of CI across eukaryotes. Respiratory complex I (CI)
Dong‐Woo Shin   +2 more
wiley   +1 more source

A four-stage process that identified a hydroxypropyl beta cyclodextrin and polysorbate containing formulation that eliminated aggregation of recombinant human NELL-1 after exposure to extrinsic stresses

open access: yesAAPS Open
Background Recombinant human NELL-1 (rhNELL-1) is a potent osteogenic protein with therapeutic potential in regenerative medicine. A stable formulation is essential to prevent aggregation during production, filling, storage, and clinical use. Methodology
Lun Xin   +6 more
doaj   +1 more source

Impact of the Human Genome Project at the Interface between Patent and FDA Laws [PDF]

open access: yes, 1996
Mr. Cunningham stresses the broad scope of biotechnological innovations. Besides endorsing the need for a new oversight commission to deal with potential social issues, he suggests, for example, that some products should be treated like biologics rather ...
Cunningham, Brian C.
core   +1 more source

Home - About - Disclaimer - Privacy